Prana's Novel Alzheimer's Drug Fails Phase II Trial, Future Uncertain
This article was originally published in PharmAsia News
Executive Summary
Australia's Prana Biotechnology said a drug for treating Alzheimer's disease failed a Phase II study, possibly dooming the small firm's chances of conducting a larger Phase III trial.